Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...
US mRNA specialist Moderna today announced positive preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...
Moderna (MRNA) announced preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE, which targets the LP.8.1 variant of SARS-CoV-2 to ...
Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and ...
Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...
Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.
Moderna said on Tuesday its updated COVID-19 vaccine elicited a strong immune response in all adults age 65 and older, as ...
Moderna (MRNA) stock is in focus as its updated mNEXSPIKE COVID vaccine boosts antibodies 15-fold on average against the new ...
Asianet Newsable on MSN
Moderna Says Updated mNEXSPIKE Covid Shot Demonstrated Robust Immune Response In Study
Moderna (MRNA) said on Tuesday that its 2025-2026 formula of mNEXSPIKE demonstrated a strong immune response in recipients in ...
Moderna said its updated mNexspike Covid-19 vaccine demonstrated a strong immune response against the dominant LP.8.1 variant, after previously saying its other Covid-19 vaccine, Spikevax, also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback